Cipla Ltd (CIPLA)
₹1,410.60
Mkt cap
₹1.14L Cr
P/E ratio
31.80
P/B
3.31
Div yield
0.92%
ROE
11.60%
ROCE
15.50%
EPS (TTM)
₹44.36
Book value
₹426
52W range
1,192–1,664
Sector
Healthcare
Incorporated in 1935, Cipla Ltd is in the business of manufacturing, developing, and marketing a wide range of branded and generic formulations and APIs [1]
Health check
Mixed
ValuationFair
ProfitabilityAverage
GrowthModerate
TechnicalsNeutral
52-week range
−15.21% from high₹1,411
₹1,192+18.30% from low₹1,664
Current
₹1,410.60
Prev close
₹1,409.00
Day
+0.11%
Price performance
1D
+0.11%
1W
−2.15%
1M
−2.05%
3M
+8.93%
6M
+2.34%
1Y
−4.84%
YTD
−6.68%
Financials
FRevenue, profit & margin
P/E ratio
31.8×
CIPLA is 6% below the sector median of 33.9×
CIPLA31.8×
Sector median33.9×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6,329 | 6,678 | 6,604 | 6,163 | 6,694 | 7,051 | 7,073 | 6,730 | 6,957 | 7,589 | 7,074 | 6,541 | 7,119 | |
| Expenses | 4,835 | 4,944 | 4,856 | 4,847 | 4,978 | 5,165 | 5,084 | 5,192 | 5,179 | 5,695 | 5,819 | 5,586 | 5,927 | |
| Operating Profit | 1,494 | 1,734 | 1,748 | 1,316 | 1,716 | 1,886 | 1,989 | 1,538 | 1,778 | 1,895 | 1,255 | 955 | 1,192 | |
| OPM % | 24% | 26% | 26% | 21% | 26% | 27% | 28% | 23% | 26% | 25% | 18% | 15% | 17% | |
| Other Income | 136 | 176 | -10 | 249 | 160 | 191 | 222 | 289 | 259 | 269 | -70 | 148 | 211 | |
| Interest | 16 | 26 | 30 | 18 | 18 | 15 | 15 | 14 | 14 | 13 | 14 | 13 | 17 | |
| Depreciation | 239 | 290 | 233 | 288 | 247 | 272 | 280 | 309 | 253 | 297 | 278 | 383 | 304 | |
| Profit before tax | 1,375 | 1,594 | 1,474 | 1,259 | 1,611 | 1,789 | 1,916 | 1,504 | 1,770 | 1,854 | 893 | 707 | 1,082 | |
| Tax % | 28% | 28% | 28% | 26% | 27% | 27% | 17% | 19% | 27% | 27% | 24% | 22% | 27% | |
| Net Profit | 998 | 1,155 | 1,068 | 932 | 1,175 | 1,305 | 1,575 | 1,214 | 1,292 | 1,353 | 674 | 543 | 786 | |
| EPS in Rs | 12.33 | 14.01 | 13.08 | 11.63 | 14.58 | 16.13 | 19.45 | 15.13 | 16.06 | 16.73 | 8.37 | 6.87 | 9.77 | |
| Raw PDF |
Earnings
EResults dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.15% · closed higher next day 22 of last 62
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 28 Oct '23◦ | 22 Jan '24◦ | 11 May '24◦ | 26 Jul '24◦ | 29 Oct '24◦ | 29 Jan '25 | 13 May '25◦ | 25 Jul '25 | 30 Oct '25 | 23 Jan '26 | 13 May '26 | 23 Jul '26 |
| Earnings day | +1.64% | +7.05% | +5.61% | −1.34% | −4.01% | +0.24% | −1.66% | +3.00% | −2.59% | −4.04% | +2.73% | −1.56% |
| +1 day | +2.19% | +7.68% | +1.33% | −2.93% | +5.02% | +2.59% | −1.18% | +5.65% | −5.05% | −4.19% | +11.17% | −0.43% |
| +5 days | +2.54% | +2.64% | +4.82% | −3.81% | +6.67% | +2.00% | −2.48% | +1.00% | −4.77% | −4.29% | +8.30% | — |
| +15 days | +6.73% | +8.29% | +8.42% | −0.77% | +1.74% | +4.33% | −3.17% | +5.20% | −4.38% | −1.02% | +8.23% | — |
| +30 days | +3.60% | +12.84% | +11.96% | +3.62% | −1.97% | +2.37% | −0.66% | +4.28% | −4.03% | −2.69% | +11.44% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
CLast 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 13 Per Share | 13.00 | 5 Jun '26 | 5 Jun '26 |
Results analysis
Shareholding
Sas of Jun 202629.22%Promoter
Promoters29.22%
FIIs20.20%2.35
DIIs34.35%2.64
Public15.93%0.33
Government0.28%0.01
Ownership trend
Peers
P7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,941.10 | 37.48 | 4,65,723 | 0.82% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹7,248.50 | 73.36 | 1,92,425 | 0.41% | 751 | +13.44% | 2,831 | +9.52% | 21.97% |
| Torrent Pharma. | ₹4,961.50 | 86.10 | 1,88,697 | 0.77% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,410.60 | 31.84 | 1,13,955 | 0.92% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Zydus Lifesci. | ₹1,108.70 | 20.38 | 1,10,593 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.14% |
| Lupin | ₹2,370.50 | 19.06 | 1,08,401 | 0.76% | 1,469 | +101.49% | 7,475 | +31.89% | 29.93% |
| Mankind Pharma | ₹2,507.20 | 51.44 | 1,03,559 | 0.04% | 559 | +34.23% | 3,443 | +11.81% | 13.53% |
| Median: 157 Co. | ₹432.05 | 33.93 | 1,970 | 0.10% | 15 | +28.10% | 176 | +17.66% | 15.10% |
Filings
DAnnual reports15
Financial Year 2026bseFinancial Year 2025bseFinancial Year 2024bseFinancial Year 2023bseFinancial Year 2022bseFinancial Year 2021bseFinancial Year 2020bseFinancial Year 2019bseFinancial Year 2018bseFinancial Year 2017bseFinancial Year 2016bseFinancial Year 2015bseFinancial Year 2014bseFinancial Year 2013bseFinancial Year 2012bse
Concall transcripts105
PPTJul 2026RECJul 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptJan 2026PPTJan 2026RECJan 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptJul 2025PPTJul 2025RECJul 2025TranscriptMay 2025PPTMay 2025TranscriptFeb 2025PPTFeb 2025PPTJan 2025TranscriptNov 2024PPTNov 2024TranscriptJul 2024PPTJul 2024TranscriptMay 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 3h - Please find attached newspaper intimation for unaudited financial results for the quarter ended 30th June, 2026.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 24h - Audio recording of Q1 FY2027 earnings conference call available on Cipla website.Intimation Under Regulation 30(5) Of The SEBI (LODR) Regulations, 2015 1d - Board approved changes in Cipla’s KMPs and Regulation 30(5) authorized officers effective 24 July 2026.Grant Of Stock Option And Employee Stock Appreciation Rights 1d - Cipla granted 5,530 stock options and 19,179 ESARs on 23 July 2026.Announcement under Regulation 30 (LODR)-Change in Management 1d - Board approved reporting change for Head API Business; Mr. Sanjay Joseph ceases as SMP24 July 2026.